Open AccessEffects of preemptive analgesia with flurbiprofen ester on lymphocytes and natural killer cells in patients undergoing esophagectomy: A randomized controlled pilot study
Author(s) -
Zhou Yi,
Huang Jinxi,
Bai Yu,
Li Changsheng,
Lu Xihua
Publication year - 2017
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12502
Subject(s) - medicine , thoracoscopy , thoracotomy , esophagectomy , anesthesia , analgesic , esophageal cancer , immune system , flurbiprofen , surgery , randomized controlled trial , gastroenterology , cancer , immunology
Background Tumors may induce systemic immune dysfunction, which can be aggravated by surgery and anesthesia/analgesia. Data on the effect of flurbiprofen preemptive analgesia on immune dysfunction is limited. The aim of this study was to investigate the effect of flurbiprofen preemptive analgesia on lymphocytes and natural killer ( NK ) cells in patients undergoing thoracotomy and thoracoscopy radical esophagectomy, and to explore the analgesic methods suitable for tumor patients. Methods This was a randomized controlled pilot study of 89 patients with esophageal cancer treated with surgery at the H enan C ancer H ospital between J anuary 1, 2015 and D ecember 31, 2016. The patients were divided into three groups: group 1, thoracotomy; group 2, thoracoscopy and laparoscopic surgery; and group 3, flurbiprofen, thoracoscopy, and laparoscopic surgery. CD 3+, CD 19+, NK , CD 4+, and CD 8+ cells in whole blood were measured by flow cytometry 30 minutes before surgery ( T 0), at the end of the thoracic section of the procedure ( T 1), and at the end of the operation ( T 2). Results There were no significant differences in CD 3+, CD 19+, CD 8+, NK , and CD 4+ cells between the three groups or regarding the time points during the procedure (all P > 0.05). Thoracotomy and thoracoscopy surgery resulted in similar immunological outcomes. Conclusion Flurbiprofen ester preemptive analgesia did not suppress the immune function in patients and could be a safe analgesic method for patients with esophageal cancer undergoing surgery.